Complete Summary

GUIDELINE TITLE

Care of the patient with strabismus: Esotropia and exotropia.

BIBLIOGRAPHIC SOURCE(S)

American Optometric Association. Care of the patient with strabismus: esotropia and exotropia. 2nd ed. St. Louis (MO): American Optometric Association; 1996. 69 p. (Optometric clinical practice guideline; no. 16). [115 references]

GUIDELINE STATUS

This is the current release of the guideline.

According to the guideline developer, this guideline has been reviewed on a biannual basis and is considered to be current as of 2004. This review process involves updated literature searches of electronic databases and expert panel review of new evidence that has emerged since the original publication date.

COMPLETE SUMMARY CONTENT

SCOPE

METHODOLOGY - including Rating Scheme and Cost Analysis RECOMMENDATIONS

EVIDENCE SUPPORTING THE RECOMMENDATIONS

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS QUALIFYING STATEMENTS

IMPLEMENTATION OF THE GUIDELINE

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IDENTIFYING INFORMATION AND AVAILABILITY DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

Strabismus:

- Esotropia
 - Infantile Esotropia
 - Acquired Esotropia
 - Secondary Esotropia
 - Microesotropia
- Exotropia

- Infantile Exotropia
- Acquired Exotropia
- Secondary Exotropia
- Microexotropia

GUIDELINE CATEGORY

Diagnosis Evaluation Management

CLINICAL SPECIALTY

Optometry

INTENDED USERS

Health Plans Optometrists

GUIDELINE OBJECTIVE(S)

- To identify patients at risk of developing strabismus
- To accurately diagnose strabismus
- To improve the quality of care rendered to patients with strabismus
- To minimize the adverse effects of strabismus and enhance the patient's quality of life
- To preserve the gains obtained through treatment
- To inform and educate other health care practitioners including primary care physicians, teachers, parents, and patients about the visual complications of strabismus and the availability of treatment.

TARGET POPULATION

Children and adults with suspected or diagnosed strabismus.

INTERVENTIONS AND PRACTICES CONSIDERED

- A. Diagnosis
 - 1. Patient History
 - 2. Ocular Examination
 - Visual Acuity
 - Ocular Motor Deviation
 - Monocular Fixation
 - Extraocular Muscle Function
 - Sensorimotor Fusion
 - Accommodation
 - Refraction
 - Ocular Health Assessment and Systemic Health Screening
- B. Treatment
 - 1. Optical Correction

- 2. Added Lens Power
- 3. Prisms
- 4. Active Vision Therapy
- 5. Pharmacological Agents
- 6. Extraocular Muscle Surgery
- 7. Chemodenervation
- C. Patient Education

MAJOR OUTCOMES CONSIDERED

Not stated

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources) Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The guideline developer performed literature searches using the National Library of Medicine's Medline database and the VisionNet database.

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Expert Consensus (Committee)

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

METHODS USED TO ANALYZE THE EVIDENCE

Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not applicable

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Internal Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

The Reference Guide for Clinicians was reviewed by the American Optometric Association (AOA) Clinical Guidelines Coordinating Committee and approved by the AOA Board of Trustees.

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Diagnosis of Strabismus

The examination of strabismic patients generally includes all areas of the evaluation of a comprehensive adult or pediatric eye and vision examination. The evaluation of sensory, motor, refractive, and accommodative functions requires further, in-depth examination. Additional office visits may be required to complete the examination process, especially with younger children.

The evaluation of a patient with strabismus may include, but is not limited to, the following components. Professional judgment and individual patient symptoms and findings may have significant impact on the nature, extent, and course of the services provided.

- 1. Patient History
- 2. Ocular Examination
 - a. Visual Acuity
 - b. Ocular Motor Deviation
 - c. Monocular Fixation
 - d. Extraocular Muscle Function
 - e. Sensorimotor Fusion
 - f. Accommodation
 - q. Refraction
 - h. Ocular Health Assessment and Systemic Health Screening

Management of Strabismus

The extent to which an optometrist can provide treatment for strabismus may vary depending on the state's scope of practice laws and regulations and the individual optometrist's certification. Management of the patient with strabismus may require consultation with or referral to an ophthalmologist for those services outside the optometrist's scope of practice.

The management of the strabismic patient is based on the interpretation and analysis of the examination results and overall evaluation. The goals of treatment may include (1) obtaining normal visual acuity in each eye, (2) obtaining and/or improving fusion, (3) eliminating any associated sensory adaptations, and (4) obtaining a favorable functional appearance of the alignment of the eyes. The significance of normal ocular alignment for the development of a positive self-image and interpersonal eye contact cannot be overemphasized.

The indications for and specific types of treatment need to be individualized for each patient.

The treatment of strabismus may include any or all of the following procedures:

- a. Optical Correction
- b. Added Lens Power
- c. Prisms
- d. Active Vision Therapy
- e. Pharmacological Agents
- f. Extraocular Muscle Surgery
- g. Chemodenervation

Patient Education

The prognosis, advantages, and disadvantages of the various modes of treatment should be discussed with the patient and/or the patient's parents and a plan developed based on this dialogue.

Prognosis and Follow-up

The purpose of the follow-up evaluation is to assess the patient's response to therapy and to alter or adjust treatment as needed.

The frequency and composition of evaluation and management visits for esotropia and exotropia are summarized in the following table:

Frequency and Composition of Evaluation and Management Visits for Esotropia and Exotropia

Type of Patient	Number of Evaluation Visits	Treatment Options	Frequency of Follow-Up Visits*	Management Plan
--------------------	--------------------------------------	----------------------	--------------------------------	--------------------

Accommodative esotropia	1 to 3	•	Optical correction Vision therapy	•	<6 years: every 4 to 6 mos 6 to 10 years: every 6 to 12 mos ≥11 years: every 12 mos	Provide refractive correction; treat any amblyopia; use added plus at near if needed to facilitate fusion; prescribe vision therapy to develop/enhance normal sensory and motor fusion.
Acute esotropia and exotropia	1 to 3	•	Prisms Vision therapy Surgery	٠	Every 3 to 12 mos	Use prisms to eliminate diplopia and restablish binocular vision; prescribe vision therapy; in stable deviations over 20 to 25 prism diopter (PD), consult with ophthalmologist regarding extraocular muscle surgery.
Consecutive esotropia and exotropia	1 to 3	•	Optical correction Prisms Vision therapy Surgery	•	Variable, depending on etiology	Provide refractive correction; prescribe prism and/or vision therapy to prevent amblyopia, eliminate diplopia, and establish normal sensory fusion, if applicable.
Infantile or early-acquired esotropia and exotropia	1 to 3	•	Optical correction Prisms Vision therapy Surgery	•	<2 years: every 3 mos 2 to 5 years: every 4 to 6 mos 6 to 10	Provide refractive correction; treat any amblyopia; use prism to establish normal sensory fusion,

				•	years: every 12 mos >11 years: every 12 to 24 mos	if applicable; consult with ophthalmologist regarding extraocular muscle surgery.
Intermittent exotropia	1 to 3	•	Optical correction Prisms Vision therapy Surgery	•	<5 years: every 4 to 6 mos 5 to 10 years: every 6 to 12 mos >11 years: every 12 to 24 mos	Provide refractive correction; use added minus lens power or base-in prism if needed to facilitate fusion; prescribe vision therapy; if deviation persists or increases, consult with ophthalmologist regarding extraocular muscle surgery.
Mechanical esotropia and exotropia	1 to 3	•	Prisms Surgery	•	Variable, depending on etiology	No therapy if strabismus is not present in the primary position of gaze and no diplopia. Consider prisms and/or surgery to treat head turn.
Microtropia	1 to 3	•	Optical correction Prisms Vision therapy	•	Every 3 to 12 mos	Provide refractive correction; treat any amblyopia; prescribe vision therapy and/or prism to establish bifoveal fusion, if applicable.
Sensory esotropia and exotropia	1 to 3	•	Optical correction Prisms Vision	•	Every 3 to 12 mos	Consult with ophthalmologist regarding treatment of any

therapySurgery

underlying ophthalmic disease; provide refractive correction; treat any amblyopia; prescribe vision therapy and/or prism, if applicable; if deviation persists or increases, consult with ophthalmologist regarding extraocular muscle surgery.

CLINICAL ALGORITHM(S)

An algorithm is provided for Optometric Management of the Patient with Strabismus.

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is not specifically stated for each recommendation.

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

The optometrist should emphasize the diagnosis, timely and appropriate management, and careful follow-up of patients with strabismus. Proper care can result in reduction of personal suffering for those involved as well as a substantial cost savings for the involved individuals and their families.

POTENTIAL HARMS

- Pharmacological agents may be associated with local and systemic adverse effects.
- Extraocular muscle surgery may be associated with postoperative complications including diplopia, under-corrections, overcorrections, chronic

^{*} Vision therapy would require additional visits.

inflammation of the conjunctiva, excessive scar tissue, lost muscle(s), perforation of the globe, endophthalmitis, anterior segment ischemia, and corneal dellen.

 Chemodenervation may be associated with transient ptosis and vertical strabismus.

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

Clinicians should not rely on this Clinical Guideline alone for patient care and management. Please refer to the references and other sources listed in the original guideline for a more detailed analysis and discussion of research and patient care information.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

IMPLEMENTATION TOOLS

Clinical Algorithm Patient Resources

For information about <u>availability</u>, see the "Availability of Companion Documents" and "Patient Resources" fields below.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better

IOM DOMAIN

Effectiveness Patient-centeredness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

American Optometric Association. Care of the patient with strabismus: esotropia and exotropia. 2nd ed. St. Louis (MO): American Optometric Association; 1996. 69 p. (Optometric clinical practice quideline; no. 16). [115 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1995 (revised 1999; reviewed 2004)

GUIDELINE DEVELOPER(S)

American Optometric Association - Professional Association

SOURCE(S) OF FUNDING

Funding was provided by the Vision Service Plan (Rancho Cordova, California) and its subsidiary Altair Eyewear (Rancho Cordova, California)

GUIDELINE COMMITTEE

American Optometric Association Consensus Panel on the Care of the Patient with Strabismus

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Members: Robert P. Rutstein, O.D. (Principal Author); Martin S. Cogen, M.D.; Susan A. Cotter, O.D.; Kent M. Daum, O.D., Ph.D.; Rochelle L. Mozlin, O.D.; Julie M. Ryan, O.D.

AOA Clinical Guidelines Coordinating Committee Members: John F. Amos, O.D., M.S. (Chair); Barry Barresi, O.D., Ph.D.; Kerry L. Beebe, O.D.; Jerry Cavallerano, O.D., Ph.D.; John Lahr, O.D.; David Mills, O.D.

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

According to the guideline developer, this guideline has been reviewed on a biannual basis and is considered to be current as of 2004. This review process involves updated literature searches of electronic databases and expert panel review of new evidence that has emerged since the original publication date.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from the American Optometric Association Web site.

Print copies: Available from the American Optometric Association, 243 N. Lindbergh Blvd., St. Louis, MO 63141-7881

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

The following is available:

• Answers to your questions about strabismus. St. Louis, MO: American Optometric Association. (Patient information pamphet).

Print copies: Available from the American Optometric Association, 243 N. Lindbergh Blvd., St. Louis, MO 63141-7881; Web site, www.aoanet.org.

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

NGC STATUS

This summary was completed by ECRI on December 1, 1999. The information was verified by the guideline developer on January 31, 2000.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions as follows:

Copyright to the original guideline is owned by the American Optometric Association (AOA). NGC users are free to download a single copy for personal use. Reproduction without permission of the AOA is prohibited. Permissions requests should be directed to Jeffrey L. Weaver, O.D., Director, Clinical Care Group, American Optometric Association, 243 N. Lindbergh Blvd., St. Louis, MO 63141; (314) 991-4100, ext. 244; fax (314) 991-4101; e-mail, Jlweaver@AOA.org.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.quideline.gov/about/inclusion.aspx.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 11/3/2008

